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Kadamba Papavinasasundaram, James M. Bean, Christopher M. Sassetti, Alfonso Mendoza-Losana,
Gurdyal S. Besra, Mary Jackson, and Dirk Schnappinger*
Cite This: ACS Infect. Dis. 2021, 7, 141−152 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: MmpL3, an essential mycolate transporter in the
inner membrane of Mycobacterium tuberculosis (Mtb), has been
identified as a target of multiple, chemically diverse antitubercular
drugs. However, several of these molecules seem to have secondary
targets and inhibit bacterial growth by more than one mechanism.
Here, we describe a cell-based assay that utilizes two-way
regulation of MmpL3 expression to readily identify MmpL3-
specific inhibitors. We successfully used this assay to identify a
novel guanidine-based MmpL3 inhibitor from a library of 220
compounds that inhibit growth of Mtb by largely unknown
mechanisms. We furthermore identified inhibitors of cytochrome
bc1-aa3 oxidase as one class of off-target hits in whole-cell screens for MmpL3 inhibitors and report a novel sulfanylacetamide as a
potential QcrB inhibitor.
KEYWORDS: targeted whole-cell screen, mycolic acids, antibiotics, molecular genetics, drug discovery, respiration
M ycobacterium tuberculosis (Mtb), etiologic agent oftuberculosis (TB), is the leading cause of adult
mortality due to a single infectious agent in both healthy and
HIV-infected individuals. In 2019, the World Health
Organization (WHO) estimated a total of 1.7 billion people
to be infected with Mtb and at risk of developing the disease.1
The preferred treatment for drug-susceptible TB requires at
least four drugs with toxic side effects, administered routinely
for a minimum of two months during the intensive phase and
at least two drugs during the continuation phase of four
months.1 This leads to poor compliance, which accelerates the
emergence of drug-resistance, and causes relapse of disease.2,3
Reducing the global TB epidemic necessitates development of
new therapeutics to shorten the duration of treatment and to
be effective against the drug-resistant forms of infection.
To facilitate TB drug discovery efforts, whole-cell screens
(WCS) against Mtb have identified the highest number of
novel pharmacophores with potent antimycobacterial activ-
ity.4,5 Interestingly, multiple chemical entities discovered using
this approach primarily target MmpL3, an essential lipid
transporter in mycobacteria.6−14 A member of the resistance
nodulation and division (RND) superfamily of transporters,
MmpL3 facilitates transport of trehalose monomycolate
(TMM) into the periplasmic space where it is modified and
assembled into the outer layer of the mycobacterial cell
envelope.15−17 Chemical and genetic inhibition of MmpL3
leads to a sharp decline in mycolate transport, bacterial growth,
and viability, both in vitro and in the mouse model of TB,
rendering it a significant target of therapeutic inter-
est.6−10,18−21 Anti-MmpL3 pharmacophores, including ada-
mantyl ureas,9 pyrroles,7 indolecarboxamides,20 diamines,6,22
tetrahydropyrazolopyrimidines (THPPs), and spirocycles
(Spiros),8,23 are active against drug-resistant strains of Mtb.
In addition, several of these scaffolds synergize with existing
antitubercular drugs, for example, rifampicin, suggesting that
inhibition of MmpL3 could shorten TB treatment.8,10,24−29
Among these pharmacophores, the diamine SQ109 has
successfully completed phase 2b-3 of clinical trials30,31 and
others such as indolecarboxamides, pyrroles, and THPPs
exhibit favorable pharmacokinetic profiles and efficacy in
murine models of infection.7,8,10
To date, identification and characterization of MmpL3
inhibitors relies on integration of cell-based screenings of
chemical libraries with genetic techniques, such as isolating
resistant mutants and performing cross-inhibition experiments,
followed by chemical-radiolabeling to assess TMM levels to
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identify the target. While informative, most of these methods
are laborious, compound-intensive, and difficult to implement
in a high-throughput format, hence limiting their utility. The
need to simplify identification of MmpL3 inhibitors was
recently addressed by an elegant study, which utilized a pool of
24 unique mmpL3 mutants. Each mutant caused resistance
against a subset of the known MmpL3 inhibitors. This
increases screening efficiency significantly, but only for
compounds susceptible to already known resistance muta-
tions.32 Furthermore, a cohort of MmpL3 inhibitors, including
THPPs, seems to impede bacterial growth either by inhibition
of multiple targets23,33 or by general mechanisms, such as
dissipation of proton motive force (PMF), necessary for
substrate translocation, rendering it difficult to distinguish
between on- and off-target inhibitors of this target.34,35
Here, we report a whole-cell assay encompassing a
transcriptionally regulated strain of MmpL3, mmpL3-TetON,
with two-way regulation of protein expression in Mtb to
identify and segregate on-target inhibitors. We first charac-
terized the consequences of regulating MmpL3 on growth,
membrane permeability, and susceptibility to known MmpL3
inhibitors and existing antibiotics. Next, we performed a cell-
based phenotypic screen utilizing the mmpL3-TetON strain
against 220 compounds comprising the GSK-Tres Cantos
antimycobacterial set (TB-set) to identify new inhibitors in
addition to validating the previously characterized scaffolds.
Furthermore, using an Mtb knockout of cytochrome bd
oxidase, we could discern inhibitors of cytochrome bc1-aa3
oxidase as most likely to indirectly interfere with MmpL3
activity. This approach identified a sulfanylacetamide as a
probable cytochrome bc1-aa3 oxidase inhibitor. Finally, we
established a guanidine-based compound, CCI7967, as an on-
target inhibitor of MmpL3. Our work highlights the value of
target-based phenotypic screens to identify novel antimyco-
bacterial inhibitors. These assays have significant utility in
facilitating prompt identification of new lead molecules and
target-driven optimization of analogues of more advanced
scaffolds that inhibit MmpL3 activity in a cellular context.
■ RESULTS
Consequences of Two-Way Regulation of MmpL3 on
Growth, Protein Expression, and Susceptibility to On-
Target MmpL3 Inhibitors. We constructed a transcription-
ally regulated MmpL3 strain, mmpL3-TetON, as previously
described for trxB2.36 The mmpL3-TetON strain and wild-type
H37Rv (WT) grew with similar kinetics in either the absence
or presence of 500 ng/mL of anhydrotetracycline (ATc)
(Figure 1A). MmpL3 expression was quantified by LC-MS/
MS using MmpL3-specific peptides and normalized to the
essential sigma factor SigA of RNAP, which is constitutively
expressed during growth and commonly used as reference in
expression studies.37 Compared to WT, mmpL3-TetON with
ATc displayed a 717% increase in MmpL3 expression while its
cultivation in ATc-free media resulted in an 80% decrease
(Figure 1B). Therefore, mmpL3-TetON provides two-way
regulation, overexpression, and under-expression of MmpL3,
without compromising the growth of Mtb.
Next, we examined the susceptibility of mmpL3-TetON
toward the clinical candidate SQ109 (diamine) (Figure 1C)
and three other compounds, IC2418 (indolecarboxamide)
(Figure 1D), BM212 (pyrrole) (Figure 1E), and AU1235
(adamantyl urea) (Figure 1F), that reduce the growth of Mtb
via inhibition of MmpL3. All four compounds were more
potent against mmpL3-TetON than WT when both strains
were grown without ATc and less potent against mmpL3-
TetON when grown with ATc (Figure 1C−F, Table S1). The
dose−response profiles thus showed a bidirectional shift in
IC50 in response to MmpL3 regulation, suggesting that
mmpL3-TetON could be used to identify inhibitors of
MmpL3.
Figure 1. Consequences of two-way regulation of mmpL3 on growth, protein expression, and susceptibility to on-target MmpL3 inhibitors. (A)
Growth and (B) protein levels of MmpL3 in mmpL3-TetON in the absence and presence of inducer ATc. (C−F) Dose−response profiles of
MmpL3 inhibitors against mmpL3-TetON (orange) in the absence (open, dashed) and presence (closed, solid) of ATc (500 ng/mL) vs WT
(black). Data are representative of three experiments; values are averages of two technical replicates and error bars represent the standard error
(SE) of the mean. See also Table S2.
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Compounds Indirectly Affected by MmpL3 Display a
Unidirectional Shift against mmpL3-TetON. Next, we
investigated the potency of chemically and mechanistically
diverse antibiotics toward WT and mmpL3-TetON. The
potency of 22 antibiotics (Figure S1) was similar against
mmpL3-TetON and WT when grown in the absence of ATc.
This included fluoroquinolones, such as ciprofloxacin, and
mycolate synthesis inhibitors, such as isoniazid, that behaved as
previously reported.38 However, when cultivated without ATc,
mmpL3-TetON was hyper-sensitized to rifampicin (Figure
2A), clarithromycin (Figure 2B), erythromycin, fidaxomicin
(Figure S2), and fusidic acid (Figure S2). MmpL3 depletion
also increased activity of different β-lactams, cephalexin
(Figure 2C), cefadroxil, cefdinir (Figure S2), ampicillin (Figure
2D), carbenicillin (Figure S2), doripenem (Figure 2E),
imipenem, and faropenem (Figure S2). In contrast to the
direct inhibitors of MmpL3 activity, the potency of these
compounds did not shift for mmpL3-TetON when grown in
the presence of ATc. A unidirectional MIC shift thus
distinguished compounds that were affected indirectly by a
reduction in MmpL3 expression from direct MmpL3 inhibitors
that had displayed a bidirectional MIC shift.
MmpL3 mediates the transport of TMM, which suggests
that reducing its expression could alter the fluidity of the
mycobacterial cell envelope and modify its permeability.39,40
To test this, we performed an ethidium bromide (EtBr)-based
uptake assay41 for WT and mmpL3-TetON. When grown with
ATc, EtBr uptake of mmpL3-TetON was similar to that of WT
(Figure 2F). However, when grown without ATc, mmpL3-
TetON exhibited a 3-fold increase in EtBr uptake relative to
the WT. The increased susceptibility that resulted from under-
expression of MmpL3 for growth inhibition by mechanistically
diverse drugs such as rifampicin, clarithromycin, erythromycin,
and fidaxomicin, which are all large (>500 Da) and
hydrophobic (log P > 2.5), might thus be due to differences
in drug uptake. Conversely, the increased potency of
hydrophilic antibiotics such as β-lactams could be governed
by defects in outer membrane permeability or by mechanisms
not entirely understood.
Figure 2. Silencing of MmpL3 expression alters cell envelope permeability to specific off-target inhibitors. (A−E) Dose−response profiles of
mmpL3-TetON (orange) in the absence (open, dashed) and presence (closed, solid) of ATc (500 ng/mL) against high molecular weight
antibiotics (A) rifampicin and (B) clarithromycin; and to different classes of (C−E) β-lactams. Data are representative of three experiments; values
are averages of three technical replicates and error bars represent the SE of the mean. (F) Impact of MmpL3 depletion on accumulation of EtBr.
The strains were incubated with 8 μg/mL of EtBr in PBS supplemented with 0.05% Tyloxapol and 0.4% Glucose. Reads were collected every
minute until 60 min at 37 °C. See also Figure S2.
Figure 3. Susceptibility profile of mmpL3-TetON against the on-target hits. (A−C) Impact of selected screening hits on mmpL3-TetON (orange)
and WT (black). For mmpL3-TetON, measurements were performed without (open squares, dotted lines) and with (closed squares, solid lines)
ATc (500 ng/mL). Data are representative of three biological and two technical replicates. See also Figure S3 and Table S1.
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Targeted Whole-Cell Phenotypic Screen to Identify
Inhibitors of MmpL3 Function. To investigate the utility of
two-way regulation in identifying scaffolds that inhibit
mycolate transport, we evaluated mmpL3-TetON and WT
against a library of 220 compounds in the GSK Tb-set.5,42
Bacteria were grown without ATc and subjected to up to 10
doses of the compounds with concentrations ranging between
100 and 0.005 μM including 1% DMSO (negative control)
and 1 μg/mL rifampicin (positive control). The screen
presented a Z′ value >0.8. Compounds that inhibited the
growth of WT by at least 30% at the highest concentration
were re-evaluated against WT and mmpL3-TetON with and
without ATc. This identified 26 hits (Table S1, Figure S3),
which were then assessed for changes in IC50. All 26
compounds displayed a decrease in IC50 against the mmpL3-
TetON without ATc. Of these, 12 compounds displayed >1.5-
fold increase in IC50 against mmpL3-TetON with ATc, which
were categorized as on-target hits. Six of the on-target hits
(denoted with * in Table S1) were excluded from subsequent
analyses due to lack of availability and poor solubility. The
remaining hits were distributed in three scaffolds including
Spiros (Figure 3A and Table S1),8 oxadiazoles (Figure 3B and
Table S1),43 and THPPs (Figure 3C and Table S1).8
Interestingly, we observed inconsistency in phenotype for
members of two scaffolds, Spiros (SB-354364, Table S1) and
cycloalkanes (GSK2783100A*, Table S1),44 as neither
confirmed to target MmpL3. The singleton hydroxypiperidine
(GSK1985270A, Table S1) that seems to target MmpL3 in
both Mtb and Mycobacterium abscessus (Mab)45,46 displayed no
change in potency against the mmpL3-TetON with ATc.
The THPPs identified herein accounted for 42% of the on-
target hits with all presenting a bidirectional shift of the highest
magnitude of the scaffolds tested. Mutations conferring THPP
resistance also map to one target, MmpL3,34,47 and THPPs
bind MmpL3,34 rendering it a pivotal target. However, THPPs
also interact with an enoyl-coenzyme A hydratase, EchA6, to
suppress mycolic acid synthesis, deeming it a second target.23
We confirmed the stereospecificity of new THPPs for EchA6
(Figure S4) in an intrinsic tryptophan fluorescence binding
assay against the purified Mtb-EchA6.23 As expected, the
compounds bound with a KD ranging from 0.62−6.86 μM,
similar to the previously reported THPPs, GSK366A (KD =
1.01 ± 0.38 μM) and GSK951A (KD = 0.64 ± 0.16 μM)
further supporting EchA6 as a second target.
Partial Expression of MmpL3 Identifies Inhibitors of
Cytochrome bc1-aa3. The crystal structure of MmpL3
defined a dedicated H+ translocation channel in the protein
that drives the translocation of TMM across to the periplasmic
space.35 Co-crystal structures and molecular docking studies
suggest that most MmpL3 inhibitors reduce TMM trans-
location by binding and blocking the H+ relay channel.35 This
motivated us to further explore the relationship between
membrane polarization and MmpL3 activity. We first analyzed
the impact of MmpL3 expression on the membrane potential
(ΔΨ) using the ΔΨ-sensitive cyanine dye DiOC2(3).48 Red
fluorescence of DiOC2(3) indicates an intact membrane
potential, whereas its dissipation, for example, by treatment
with the PMF uncoupler CCCP, is accompanied by a shift
from red to green fluorescence. DiOC2(3) fluorescence of
mmpL3-TetON grown with ATc was similar to that of WT but
red-shifted when grown without ATc. This suggested that
MmpL3 under-expression led to an increase in ΔΨ, as
reported previously,32,34 while its overexpression led to a small
decrease in ΔΨ (Figure 4A).
RND transporters rely on PMF and PMF-disrupters, such as
CCCP, can inhibit the RND transport activity.33 Molecules
that affect the electron transport chain (ETC), which is
responsible for generation and maintenance of PMF, could
thus represent one class of inhibitors whose potency increases
upon MmpL3 under-expression without interacting with
MmpL3 directly. We tested the impact of MmpL3 under-
expression on ETC inhibitors with Q20349 and bedaqui-
line,50,51 that inhibit Mtb’s cytochrome bc1-aa3 oxidase and
ATP synthase, respectively. Silencing of MmpL3 only had a
modest effect on bedaquiline but enhanced the activity of
Q203 (Figure 4B,C), which identified inhibitors of cytochrome
bc1-aa3 oxidase as potential off-target hits.
Furthermore, the hits we classified as indirect inhibitors of
MmpL3 included two scaffolds, imidazopyridine amine (IPA)
and quinolone (QoA), reported to target cytochrome bc1-aa3
oxidase.52,53 The cytochrome bc1-aa3 oxidase functions in
conjunction with cytochrome bd oxidase and inactivation of
both leads to rapid killing of Mtb.54 Accordingly, inhibitors of
cytochrome bc1-aa3 oxidase are more potent against a knockout
of cytochrome bd oxidase (ΔcydABDC) than WT.55 To
Figure 4. Impact of MmpL3 expression on membrane potential and the activity of ETC inhibitors. (A) Effect on membrane potential (ΔΨ).
DiOC2(3) accumulation was assessed in mmpL3-TetON in the presence and absence of ATc (500 ng/mL) before (solid) and after (hollow)
exposure to 500 μM CCCP for 30 min at 37 °C. Student’s unpaired t test (p < 0.01) was performed to determine statistical significance of
differences between the mutant groups denoted with **. (B,C) Dose−response profile of mmpL3-TetON (orange) in absence (open, dashed) and
presence (closed, solid) of ATc (500 ng/mL) against (B) the ATP synthase inhibitor bedaquiline and (C) the cytochrome bc1-aa3 inhibitor Q203.
Data are representative of three experiments; values are averages of three technical replicates and error bars represent the SE of the mean.
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investigate whether the remaining off-target scaffolds included
additional cytochrome bc1-aa3 oxidase inhibitors, we measured
their activity against ΔcydABDC. In concordance with previous
results,55 the MIC of bedaquiline against the ΔcydABDC
remained relatively unchanged (Figure 5A) whereas the MIC
of Q203 decreased substantially (Figure 5B). A sulfanylaceta-
mide, GSK1859936A, demonstrated augmented potency akin
to Q203 (Figure 5C), suggesting cytochrome bc1-aa3 oxidase
as the target of GSK1859936A. The potency of scaffolds that
inhibit MmpL3 directly remained largely unchanged against
the knockout of cytochrome bd oxidase (Figure S5). Deletion
of cydABDC too did not change the MIC of thienopyrimidine
amines (TPAs), aminothiazoles, or pyridine-2-carboxamides,
indicating an alternative mode of growth inhibition by these
scaffolds (Figure S6). In contrast, IPAs and QoA were, as
expected, more potent against ΔcydABDC, which further
validates cytochrome bc1-aa3 as a target for these scaffolds
(Figure S7).
Guanidine-Based CCI7967 Is an MmpL3 Inhibitor.
Our screen classified CCI7967, 1-(4-Chlorophenyl)-2-[4-
methyl-6-(2-phenylethylamino) pyrimidin-2-yl] guanidine
(Figure 6A), as a direct inhibitor of MmpL3. Its IC50 was
2.4-fold lower against mmpL3-TetON than WT in the absence
of ATc and 4.3-fold higher against mmpL3-TetON than WT in
the presence of ATc (Figure 6B and Table S1). To gain further
insight into its target, we isolated spontaneous mutants to
CCI7967. Approximately 9 × 10−7 of the bacteria plated grew
on agar plates containing CCI7967 at a concentration of 4-fold
the MIC. This suggests that the frequency of resistance against
CCI7967 is similar to what has been observed for other
Figure 5. Partial expression of MmpL3 identifies a sulfanylacetamide as an inhibitor of cytochrome bc1-aa3 oxidase. Dose−responses profiles of the
cytochrome bd oxidase knockout (orange, open, dashed) and complemented strain (orange, closed, solid) vs WT (black) against (A) bedaquiline,
(B) Q203, and (C) GSK1859936A. Data are representative of three experiments; values are averages of three technical replicates and error bars
represent the SE of the mean.
Figure 6. CCI7967 is an MmpL3 inhibitor. (A) Structure of CCI7967. (B) Dose−response profile of mmpL3-TetON (orange) in the absence
(open, dashed) and presence (closed, solid) of ATc (500 ng/mL). (C) Cross-resistance depicted as the ratio of IC50 between the mutant and WT
for different mutations in MmpL3 for CCI7967, GSK2200150A (Spiros), and GSK1180781A (THPP). (D−F) Isobolograms of CCI7967 tested in
combination with (D) β-lactam, cefadroxil; (E) RNA polymerase inhibitor, rifampicin; and (F) MmpL3 inhibitor, SQ109.
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MmpL3 inhibitors, for which resistance frequencies range
between 10−7 and 10−8.7−9,20 Whole-genome sequencing
identified two SNPs, T284A and A677T, in MmpL3 that
imparted a 5- to 8-fold change in IC50 against CCI7967
(Figure 6C). We also assessed the cross-inhibitory activity of
CCI7967 toward previously reported MmpL3 resistant
mutants8 isolated against Spiros and THPP compounds to
confirm MmpL3 as the target (Figure 6C). The fold changes in
IC50 were variable, with the S591I SNP imparting up to 35-fold
resistance to CCI7967. This substitution was previously found
to confer pan-resistance to several MmpL3 inhibitors.32
Previously, a synergistic association of SQ109 with
rifampicin and β-lactams was assigned to be a signature of
MmpL3 inhibitors.19,28 On this basis, we determined if
CCI7967 synergizes with rifampicin and β-lactams. The drug
combinations were assessed in a checkerboard assay format
and the isobolograms were generated by plotting the FICA vs
FICB (Figure 6D−F). As expected, the combination of
CCI7967 with cefadroxil (Figure 6C) and rifampicin (Figure
6D) presented FICI ≤ 0.5 with a convex, inward-bowing
isobologram indicative of synergism while no significant
interaction of CCI7967 with SQ109 (Figure 6F) was evident,
suggestive of a shared target for the two inhibitors.
Collectively, these data confirm CCI7967 to be an MmpL3
inhibitor.
■ DISCUSSION
MmpL3 is essential to the integrity of the mycobacterial cell
envelope which contributes to the intrinsic resistance of
mycobacteria to antimicrobials. To facilitate discovery and
development of MmpL3 inhibitors, we developed a simple and
robust assay that utilized two-way regulation of MmpL3
expression to select for target-specific compounds. That under-
expression can be exploited to identify small-molecules that
inhibit a target of interest in Mtb has been demonstrated
previously.56−58 However, the two-way system described
herein greatly facilitates to distinguish molecules that engage
the target of interest directly from those that are potentiated
due to indirect effects. Easy to implement in HTS format,
when applied against the GSK Tb-set, this methodology
validated several of the previously identified MmpL3 inhibitors
with a few exceptions, notably, SB-354364 (Spiros), and a
closely related compound, GSK1985270A (hydroxypiperidine)
(Figure S3).8,45,46 The two cycloalkanes (GSK2623870A* and
GSK2783100A*) also displayed differences in their depend-
ence on MmpL3 expression. Since high vulnerability of
MmpL3 can potentially mask secondary effects or targets of
the selected hits, it is plausible that the variation observed in
these cases could be attributed to scaffolds having secondary
targets, as is evident for THPPs23 and for a few analogues of
Spiros.59 The likelihood of a compound from a scaffold
presenting a bidirectional shift in our assay relies on its affinity
toward MmpL3, and when structurally modified could alter
this bias in favor of the secondary target rendering it difficult to
be identified as an on-target inhibitor. An example of this was
seen for THPPs, wherein a point mutation, W133A in EchA6,
increased the in vitro MIC and effective dose in mice.23
Interestingly, THPP-resistance conferring mutations mapped
to the H+ translocation domains of MmpL3,8,35 similar to all
other MmpL3 inhibitors identified to date, suggesting that
increased efflux is not the mechanism of resistance.35
Therefore, it is likely that MmpL3’s vulnerability coupled
with its ability to bind diverse scaffolds and a range of cellular
ligands47 could render it as a sink for most compounds
consequently limiting their access to other target(s).
Molecules whose potency increased in response to MmpL3
depletion but did not decrease after MmpL3 overexpression
were classified as off-target hits. For several hits, including
TPAs (GSK237561A and GSK153890A), aminothiazoles
(GSK690382A and GSK445886A),59,60 and a pyrdine-2-
carboxamide (GSK1750922A), this classification was sup-
ported by cross-resistance measurements as IC50 values were
only affected 0.4- to 5-fold by known resistance mutations in
mmpL3 (Table S2). Inhibitors of cytochrome bc1-aa3 oxidase,
including IPA,52 QoA,53 piperazine,61 and a novel sulfanyla-
cetamide (GSK1859936A), were frequent off-target hits.
Enrichment of these inhibitors in our screen might be related
to the repression of genes linked to energy metabolism that has
been observed in response to inactivation of MmpL3.18 The
mechanisms underlying other off-target inhibitors likely
include increased target access, as seen for rifampicin and β-
lactams, and, potentially, inhibition of other steps in or linked
to mycolic acid synthesis or transport, a possibility that
requires further exploration.
Our assay also identified a novel guanidine, CCI7967, as an
MmpL3 inhibitor with the characteristic bidirectional shift. Its
on-target activity was further evidenced by resistance mutants
against the compound yielding mutations in MmpL3 and
cross-resistance to other SNPs in the transporter. These three
approachesunder-expression, overexpression, and identifica-
tion of resistance mutationshelped discern CCI7967 as an
on-target inhibitor, which can be confirmed in future studies by
monitoring TMM accumulation, or direct interaction with
MmpL3.34 Furthermore, the interaction of CCI7967, similar to
previously reported MmpL3 inhibitors,27 was synergistic with
rifampicin and cefadroxil but additive with SQ109. The cell-
based assays we developed can thus be used to screen for new
small molecules that inhibit the growth of Mtb in an MmpL3-
dependent manner and subsequently distinguish those
molecules that are likely to target MmpL3 directly from
those whose potency is only indirectly affected by MmpL3.
Aside Mtb, MmpL3 is emerging as an important drug-target
in other rapidly growing pathogenic nontuberculosis mycobac-
teria such as Mab.46,62−69 An arising opportunist, Mab is
inherently resistant to several of the existing antibiotics which
drastically limits the treatment options for infection.70,71 At
present, the discernment of new MmpL3 inhibitors with
activity against Mab relies on phenotypic screens46,63,66,69 and
cross-species inhibition experiments.67 Since Mab and Mtb are
closely related, the two way system described herein could
subsequently be adapted in Mab to supplement the ongoing
drug discovery efforts.
■ METHODS
Construction of mmpL3-TetON. We first generated an
mmpL3 merodiploid by integrating the constitutive mmpL3
expression plasmid pGMCS-Ptb38-mmpL3 (StrepR) into the
attachment site of the phage L5 (attL5) of M. tuberculosis
H37Rv. Next, the wild-type (WT) copy of mmpL3 was
inactivated by homologous recombination using the knockout
construct previously used to generate mmpL3-DUC.19
Deletion of the WT copy of mmpL3 resulted in H37Rv
pGMCS-Ptb38-mmpL3, in which the only copy of mmpL3 is
expressed from the attL5 site. The mmpL3-TetON was
generated by transforming H37Rv pGMCS-Ptb38-mmpL3
with the mmpL3-TetON plasmid pGMCZ-0X-T10M-P606-
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5C-mmpL3 and screening for colonies that were resistant to
zeocin and susceptible to streptomycin. Streptomycin
sensitivity assured replacement of the constitutive pGMCS-
Ptb38-mmpL3 by pGMCZ-0X-T10M-P606-5C-mmpL3. Plas-
mid replacement and regulation of MmpL3 expression was
further confirmed by protein quantification and phenotypic
assays.
Plasmids, Bacterial Strains, and General Procedures.
The WT and its derivatives were grown in Middlebrook 7H9
medium supplemented with 0.2% (v/v) glycerol, 0.05% (v/v)
tyloxapol, 0.5% (w/v) Bovine Serum Albumin (BSA, Roche),
0.2% (w/v) dextrose, and 0.085% (w/v) NaCl (ADN), or on
Middlebrook 7H10 agar supplemented with 10% (v/v) oleic
acid-albumin-dextrose-catalase (OADC; BD, Difco) and 0.5%
(v/v) glycerol at 37 °C unless otherwise specified. Hygromycin
(Roche), streptomycin (Sigma-Aldrich), kanamycin (Sigma-
Aldrich), zeocin (Thermo Fisher) and anhydrotetracycline
(ATc, Sigma-Aldrich) were used at a concentration of 50, 25,
25, and 25 μg/mL, and 500 ng/mL, respectively. For
experiments with the regulated strain, the wild-type and
mmpL3-TetON strains were cultured until mid log phase
(OD580 0.6−0.8) in the presence of 500 ng/mL ATc at 37 °C.
To trigger regulation, cells were harvested, washed, and
resuspended to an OD580 ≈ 0.05 in Middlebrook 7H9−ADN
supplemented with and without ATc and incubated for up to
seven generations (doubling time approximately 24 h) at 37
°C. Protein levels were further altered by rediluting cultures to
an OD580 ≈ 0.01 and incubated for a minimum of five
generations (doubling time approximately 24 h) under the
same growth conditions as mentioned above to perform
subsequent experiments. The knockout of cytochrome bd
oxidase (ΔcydABDC) and complement was grown as
previously described.55
Identification and Quantitation of MmpL3 by LC-MS/
MS. The transcriptionally regulated strain of mmpL3 and the
parental H37Rv were initially grown until mid log phase in the
presence of 500 ng/mL ATc at 37 °C. To trigger regulation,
cells were harvested, washed, and resuspended to an OD580 ≈
0.05 in Middlebrook 7H9−ADN supplemented with and
without ATc and incubated for up to seven generations
(doubling time approximately 24 h) at 37 °C. Protein levels
were further altered by rediluting cultures to an OD580 ≈ 0.01
in same growth conditions and incubated for a minimum of
five generations (doubling time approximately 24 h). Bacterial
lysates for targeted proteomics were prepared using a
previously published protocol.72 Briefly, protein extracts were
prepared from 30 mL cultures by bead beating pellets with
Lysing Matrix Beads (MP Biomedical) in PBS supplemented
with 2% SDS and cOmplete EDTA−protease-free inhibitor
cocktail (Roche). Lysate protein concentrations were deter-
mined using a BCA-protein assay kit (Pierce, Thermo
Scientific). Lysates corresponding to 50 μg total protein were
subjected to electrophoresis for a short distance through a 4−
20% mini PROTEAN TGX gradient gel (Bio-Rad) under
denaturing conditions for approximately 2 cm into the gel.
After staining with Novex Colloidal Blue staining kit
(ThermoFisher Scientific), and destaining with water, the gel
pieces containing almost all of the proteins were excised out,
processed for trypsin digestion and subjected to LC/MS/MS
for Parallel Reaction Monitoring (PRM) analysis similar to
that published previously.73 Briefly, a 3.0 μL aliquot of trypsin-
digested sample was directly injected onto a custom packed 2
cm × 100 μm C18 Magic 5 μm particle trap column. Peptides
were then eluted and sprayed from a custom packed emitter
(75 μm × 25 cm C18 Magic 3 μm particle) with a linear
gradient from 95% solvent A (0.1% formic acid in water) to
35% solvent B (0.1% formic acid in Acetonitrile) in 90 min at a
flow rate of 300 nanoliters per minute on a Waters Nano
Acquity UPLC system. Data dependent acquisitions were
performed on a Q Exactive mass spectrometer (Thermo
Scientific) according to an experiment where full MS scans
from 300 to 1750 m/z were acquired at a resolution of 70 000
followed by 10 MS/MS scans acquired under Higher-energy
C-trap dissociation (HCD) fragmentation at a resolution of
17 500 with an isolation width of 1.6 Da. Six tryptic peptides of
MmpL3 (residues 97−113 FQQDHPDQVLGWAGYLR,
163−182 LAGLQPVAEALTGTIATDQR, 510−523 VLQNG-
LINPADASK, 744−755 IGLGEIHLPDER, 801−829 SSPAS-
SPELTPALEATAAPAAPSGASTTR, and 882−900 STDAA-
GDPAEPTAALPIIR) and four tryptic peptides of SigA (238−
251 VALLNAEEEVELAK, 410−418 VLEIQQYAR, 479−487
FGLTDGQPR, and 488−500 TLDEIGQVYGVTR; all
annotations as per http://tuberculist.epfl.ch) were selected to
monitor the protein abundance in the samples. Three fragment
ion intensities that generated the most robust signals were
extracted from each peptide and summed to determine the
peptide abundance. Quantification of targeted peptides was
accomplished through the Skyline software (University of
Washington). The average of peptide abundance from two
technical replicates were analyzed for each sample. The relative
level of MmpL3 was calculated by normalizing the total
transition area of each of the six MmpL3 peptides to that of
each of the four SigA peptides. Data represent the mean ± SE
obtained from the normalized values.
Drug Susceptibility Assays. The compounds used in this
study were sourced from Sigma-Aldrich and GlaxoSmithKline
(GSK). Bedaquiline, Q203, Pretomanid (PA-824), and BM212
were procured from MedChemExpress. IC2418 and AU1235
were sourced from Mary Jackson, Colorado State University.
Compounds had a purity of >98%, as determined by HPLC
and 1H NMR analysis and were dissolved and stored in
dimethyl sulfoxide for use. Susceptibility assays were
performed in black/clear, flat-bottom 384-well microplates
(Grenier Bio-One) by dispensing nanoliter volume of drugs
into 2-fold dilutions with a minimum of 10 doses per drug
using an automated drug dispenser (D300e Digital Dispenser,
HP). The DMSO concentrations in all wells were normalized
to 1%, controls included DMSO at 1% and rifampicin at 1 μg/
mL for 100% growth and 100% inhibition, respectively. Mid
log phase cultures were diluted to an optical density (OD580) ≈
0.01 in fresh 7H9−ADN media and wells were seeded with 50
μL of bacteria. Inoculated plates were stacked, covered with a
sterile lid, wrapped with aluminum foil to prevent evaporation,
and allowed to incubate at 37 °C, 5% CO2 at 80% relative
humidity for up to 10 days. Growth measurements were
recorded at OD580 using a spectrophotometer (SpectraMax M5
or M2e). IC50 values were determined using the variable-slope
four-parameter nonlinear least-squares regression model in
GraphPad Prism software package (version 8).
To determine the MIC of the compound on solid media,
7H10 agar supplemented with 10% OADC and 0.5% glycerol
was used to prepare 2-fold serial dilutions of CCI7967 at
concentrations ranging from 100−0.097 μM. Mid log phase
cultures were grown to an OD580 of 0.8−1 and diluted to a
final concentration of 106 CFU/mL and 10 μL was spotted
onto each dilution. The plates were incubated at 37 °C for up
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to 4 weeks. The MIC was defined as the lowest concentration
of drug that prevented the growth of Mtb.
High Throughput Screening. The pilot screening was
performed at GSK, Tres Cantos, Spain using exponentially
growing WT and mmpL3-TetON as previously described in
Middlebrook 7H9−ADN medium and flat bottom black/clear
384-well plates (Grenier Bio-One) containing 220 compounds
of the GSK Tb-set dispensed via Echo acoustic liquid handler.
The single cell suspensions were prepared by centrifuging the
cultures at 800 rpm for 10 min. The resulting suspension of
strains was diluted to an OD580 ≈ 0.01 and dispensed onto the
compound plates using the Multidrop dispenser (Thermo
Fisher) followed by incubation at 37 °C, 5% CO2 at 80%
relative humidity for up to 10 days. Rifampicin at 1 μg/mL was
used as positive control for inhibition and DMSO was
maintained at 1%. The OD580 for two treatment groups were
read using a SpectraMax M5 and the data was analyzed using
Activity Base software to get primary hits. Subsequent
confirmatory screenings were performed with shortlisted hits
in a similar manner as described for drug susceptibility assays.
The robustness of data was assessed by Z′ factor with a value
of >0.8 as the cut off limit.
EchA6 Binding Assay. The recombinant protein, EchA6,
was expressed and purified as previously described.23 Briefly,
Escherichia coli BL21 (DE3), harboring the pET28a-echA6
vector, were grown in 1 L LB at 37 °C, 180 rpm, to OD600 of
0.4−0.6. Recombinant EchA6 expression was induced by the
addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside
(IPTG), at 16 °C for 24 h. Following harvesting, the cell
pellet was resuspended in 50 mM sodium phosphate, 600 mM
sodium chloride and 10 mM imidazole (pH 8) containing a
complete EDTA-free Protease Inhibitor Cocktail Tablet
(Roche), and cells were sonicated on ice and then centrifuged
at 27 000g (15 000 rpm) for 40 min. Recombinant EchA6 was
purified from the supernatant using immobilized metal affinity
chromatography (IMAC) by exploiting the vector-encoded
poly histidine tag. The pure protein was subsequently dialyzed
into 25 mM HEPES, 10% glycerol, and 300 mM NaCl (pH 8),
and then concentrated.
Intrinsic tryptophan fluorescence was used to assay the
binding of the compounds GSK1589673A, GSK1180781A,
GSK1589671A, and GSK1941290A, and the control com-
pounds GSK366A and GSK951A to the recombinant EchA6.
Compounds were added at increasing stoichiometric ratios
(GSK951A, 0.5−8 μM; GSK366A, 2−50 μM; GSK1589673A,
GSK1180781A, and GSK1589671A, 0.5−20 μM;
GSK1941290A, 2−100 μM to 3 μM EchA6 in 25 mM
HEPES, 10% glycerol, and 300 mM NaCl (pH 8)).
Fluorescence spectra were measured at 25 °C with an
excitation wavelength of 280 nm (5 nm slit width) and
emission wavelength of 300−400 nm (5 nm slit width),
conducted on a Hitachi F7000 Fluorescence Spectrophotom-
eter and recorded using Hitachi FL Solutions 4.6 software.
Changes in fluorescence intensities due to increasing
compound concentrations were corrected for. Data were
analyzed in GraphPad Prism 6.
Membrane Potential Measurements in Intact Mtb.
The effect of over- and under-expression of MmpL3 on
transmembrane potential (ΔΨ) in intact bacilli was
determined using fluorescence quenching of the ΔΨ-sensitive
probe 3,3′-diethyloxacarbocyanine iodide (DiOC2(3)) (Ther-
mo Fisher). WT H37Rv and mmpL3-TetON were labeled with
50 μM DiOC2(3) in fresh 7H9−ADN for up to 30 min. Excess
DiOC2(3) was washed off and an equal volume of bacteria at
an OD580 of 0.8 were then aliquoted in black 96-well plates
(clear bottom) for reading. Samples were also treated with 500
μM carbonyl cyanide m-chlorophenyl hydrazone (CCCP,
positive control). The change in fluorescence due to disruption
of ΔΨ was monitored with a fluorescence spectrophotometer
(Spectramax M2e). DiOC2(3) was excited at 485 nm, and
emission was measured at 615 and 535 nm. The red/green
(610 nm/535 nm) fluorescence intensity ratio was calculated
and used to quantify the strength of ΔΨ.
Ethidium Bromide Uptake Assay in Microtiter Plates.
Strains were grown to OD580 of 0.8−1.0 as described above.
Cells were washed once and resuspended in PBS supple-
mented with 0.02% tyloxapol and adjusted to an OD580 of 0.8.
Glucose was then added to a final concentration of 0.8% to
trigger metabolism and cells were distributed at 100 μL per
well in a black 96-well microtiter plate with clear bottoms.
Subsequently, an equal volume of ethidium bromide in PBS
supplemented with 0.02% tyloxapol and 0.8% glucose was
added to a final concentration of 4 μg/mL. The kinetics of
fluorescence was measured every minute for 60 min at 37 °C
using a fluorescence spectrophotometer (Spectramax M5,
excitation at 530 nm, emission at 590 nm). Measurements
were performed in triplicates.
Isolation of CCI7967-Resistant Mutants. Mtb H37Rv
was grown to an OD580 of 0.8−1 to get a dense inoculum
corresponding to approximately 109 bacteria. The culture was
serially diluted and 100 μL of dilutions including undiluted,
10−1, and 10−2 were cultured on 7H10 agar plates containing
CCI7967 at a concentration of 4 × MIC. Lower dilutions were
used to enumerate cell titer. Frequency of resistance was
calculated as the number of resistant CFU thus obtained per
109 bacteria plated. Twelve resistant colonies were picked and
inoculated in 5 mL of 7H9-ADN and grown to OD580 of 0.8.
The level of resistance was assessed using antibiotic
susceptibility assays as mentioned above. Four mutants were
selected, purified genomic DNA was isolated using Epicenter
MasterPure DNA/RNA isolation kit (Lucigen), sequenced,
and analyzed for SNPs.
Chromosomal DNA Sequencing and Polymorphism
Analysis. Between 150 and 200 ng of genomic DNA was
sheared acoustically and HiSeq sequencing libraries were
prepared using the KAPA Hyper Prep Kit (Roche). PCR
amplification of the libraries was carried out for 10 cycles. (5−
10) × 106 50-bp paired-end reads were obtained for each
sample on an Illumina HiSeq 2500 using the TruSeq SBS Kit
v3 (Illumina). Postrun demultiplexing and adapter removal
were performed and fastq files were inspected using FastQC.77
Trimmed fastq files were then aligned to the reference genome
(Mtb H37RvCO; NZ_CM001515.1) using bwa mem.74 Bam
files were sorted and merged using SAM tools.75 Read groups
were added and bam files deduplicated using Picard tools and
GATK best-practices were followed for SNP and indel
detection.76 The sequences thus assembled can be accessed
through GenBank (NCBI) using the accession codes
SAMN14986274 for WT (parent), and SAMN14986281 and
SAMN14986282 for the mutants with SNPs in MmpL3.
Synergy Testing. Synergistic interactions were assessed in
384-well plates using the checkerboard assay format. Plates
were dispensed using an HP D300e digital dispenser. The
fractional inhibitory concentration (FIC) for each compound
was calculated as follows: FICA = (MIC90 of compound A in
the presence of compound B)/(MIC90 of compound A).
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Similarly, the FIC for compound B (FICB) was calculated. The
FIC Index (FICI) was calculated as FICI = [FICA + FICB].
Synergy was defined by FICI values ≤0.5, antagonism by FICI
values >4.0, and no interaction by FICI values from 0.5 to 4.0.
Quantification and Statistical Analysis. Graphic data
were prepared with GraphPad Prism software and the results
were analyzed as stated in the text. Two-tailed unpaired
Student’s t test was used for the analysis of differences between
two groups. Statistical significance was defined as P < 0.05
unless otherwise stated.
Data Availability. Compound structures are available at
ChEMBL (https://www.ebi.ac.uk/chembl/) and can be
accessed using the doc ID CHEMBL2095176, previously
published in Ballell, L. et al., 2013.5
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Guillemont, J. E., Koul, A., and Meier, T. (2015) Structure of the
mycobacterial ATP synthase Fo rotor ring in complex with the anti-
TB drug bedaquiline. Sci. Adv. 1, e1500106.
(51) Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B.,
Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I.,
Guillemont, J., Bald, D., and Andries, K. (2007) Diarylquinolines
target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3,
323−324.
(52) Abrahams, K. A., Cox, J. A., Spivey, V. L., Loman, N. J., Pallen,
M. J., Constantinidou, C., Fernandez, R., Alemparte, C., Remuinan,
M. J., Barros, D., Ballell, L., and Besra, G. S. (2012) Identification of
novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis
QcrB. PLoS One 7, e52951.
(53) Phummarin, N., Boshoff, H. I., Tsang, P. S., Dalton, J., Wiles, S.,
Barry, C. E., 3rd, and Copp, B. R. (2016) SAR and identification of 2-
(quinolin-4-yloxy)acetamides as Mycobacterium tuberculosis cyto-
chrome bc1 inhibitors. MedChemComm 7, 2122−2127.
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.0c00675
ACS Infect. Dis. 2021, 7, 141−152
151
(54) Kalia, N. P., Hasenoehrl, E. J., Ab Rahman, N. B., Koh, V. H.,
Ang, M. L. T., Sajorda, D. R., Hards, K., Grüber, G., Alonso, S., Cook,
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